The Drugs Controller General of India has authorised the business launch of “Feluda”, the Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) COVID-19 check, the Council of Scientific and Industrial Research (CSIR) mentioned on Saturday.
This check makes use of an indigenously developed, cutting-edge CRISPR know-how for detection of the genomic sequence of SARS-CoV-2 virus, CSIR mentioned in an announcement.
The Tata CRISPR check achieves accuracy ranges of conventional RT-PCR assessments with faster turnaround time, cheaper tools and higher ease of use.
CRISPR is a genome modifying know-how to diagnose illnesses. The know-how has been developed by CSIR-IGIB (Institute of Genomics and Integrative Biology).
“The Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) test, powered by CSIR-IGIB (Institute of Genomics and Integrative Biology) FELUDA, received regulatory approvals today from DCGI for commercial launch, as per ICMR guidelines, meeting high quality benchmarks with 96 per cent sensitivity and 98 per cent specificity for detecting novel coronavirus,” the assertion mentioned.
The Tata CRISPR check is the world’s first diagnostic check to deploy a specifically tailored Cas9 protein to efficiently detect the virus inflicting COVID-19, it mentioned.
Moreover, CRISPR is a futuristic know-how that can be configured for detection of a number of different pathogens sooner or later.
“The Tata Group has worked closely with CSIR-IGIB and ICMR to create a high-quality test that will help the nation ramp up COVID-19 testing quickly and economically, with a “Made in India” product that is safe, reliable, affordable and accessible,” the assertion added.
Commenting on the event, Girish Krishnamurthy, CEO, TATA Medical and Diagnostics Ltd mentioned, “The approval for the Tata CRISPR check for COVID-19 will enhance the nation’s efforts in combating the worldwide pandemic.
“The commercialisation of Tata CRISPR check displays the super R&D expertise within the nation which might collaborate to rework India’s contributions to the worldwide healthcare and scientific analysis world,” he mentioned.
Anurag Agrawal, director, CSIR-IGIB, mentioned the work began by CSIR beneath the sickle cell mission for genome diagnostics and therapeutics led to new information that might be harnessed to rapidly develop new diagnostic check for SARS-CoV-2.
He emphasised that this reveals the interconnectedness of scientific information and know-how and the innovation of the younger analysis staff led by Debojyoti Chakraborty and Souvik Maiti.